
Infectious Diseases and Vaccine Landscape 2026
Why Australia and New Zealand are strategically positioned for successful clinical trials. The global infectious disease environment continues to shift at pace in 2026, driven by: Influenza remains the clearest example of how quickly pathogens can adapt, and how the industry must respond. A newly dominant influenza A(H3N2) variant, commonly referred to as the “subclade…

Regulatory Strategy for Drug and Device Development
Regulatory Strategy for Drug and Device Development. Why it must start on Day One. In the fast-paced world of life sciences innovation, the drive to “get moving” can be irresistible. Teams dive into development, eager to demonstrate progress.Yet the companies that succeed long-term are those that pause first to plan, align, and build a regulatory…

Pharmaceutical Quality Assurance Australia and NZ
The Critical Importance of Quality Assurance (QA) in Drug Development, Clinical Trials, and Importation into Australia and New Zealand. Why Pharmaceutical Quality Assurance Matters Maintaining high-quality standards throughout every stage of drug development, including nonclinical research, clinical trials, manufacturing, supply chain, and importation, is essential for protecting patient safety, ensuring product efficacy, and fulfilling regulatory…

Benefits of Bridging Clinical Trials in Australia
BRIDGING STUDIESDo you need to ‘Bridge’ the gap? When developing your global strategy, bridging trials play a crucial role in ensuring that data from one population can be effectively applied to another. The main objective of bridging clinical trials is to determine whether the results from clinical trials conducted in one population (e.g., Caucasian) can…

Choosing the Right Regulatory Affairs Consultant
Whether you are part of an established team, a start-up, an SME, or a founder, navigating the stringent requirements of the Medical Technology, Biotechnology, and Pharmaceutical (MTP) sectors can be complex and challenging. This is where partnering with the right Regulatory Affairs Consultant becomes invaluable. Understanding the Role of a Regulatory Affairs Consultant A regulatory…

Australian Government Cash Splash on High Tech Recovery
Australian science and technology sectors are talking about a ‘research revival’ as the Federal Government splashes the cash in the 2020 Budget. 2020 Budget Cash Splash Thanks to COVID-19, early October saw the first Australian federal budget delivered in a recession in 30 years. The Treasurer said personal income tax cuts, infrastructure spending, and business
Disclaimer:
The information provided is intended for general informational purposes only and does not constitute legal, professional, or any other type of advice. While every effort has been made to ensure the accuracy and reliability of the information, the authors make no representations or warranties, express or implied, regarding the completeness, suitability, or applicability of the content to specific products or situations.
